EP1.16-03 Trial of Cost-Effectiveness Analysis of Lung Cancer Surgery-Analysis in Stage IIIA Lung Cancer

Abstract

Currently, lung cancer treatment is being treated according to lung cancer treatment guidelines. Most of the guidelines so far have been prepared after studies using the EBM method have been made about treatment effects and disadvantages. On the other hand, recent clinical research has come to examine the QOL of patients and the cost-effectiveness of treatment in chemotherapy, but there has not been any report on the cost-effectiveness of surgical treatment for cancer. We examined the cost-effectiveness of surgical treatment for lung cancer. Based on the results of lung cancer treatment at home and abroad, survival time was extracted for each stage, and from this group, surgery was performed at stage IIIA (+ S group) and not performed (-S group) Group data were used. Expenses used domestic data with reference to treatment costs in the United States. Chemotherapy was based on commonly used medications for non-small cell lung cancer. Decision analysis was used for cost-benefit analysis, and effects were calculated from survival rate and quality-adjusted survival year (QALY) using the incremental cost-effectiveness ratio (ICER) as an index. If QALY after 5 years is calculated using the life-or-death only QOL score, the ICER of +S group is approximately 5.64 million yen, and the cost-effectiveness is generally superior. If QALY is obtained from the survival curve, the ICER of +S group after 1 year is 4.97 million yen, and the cost utility analysis is even better. In this study, performing surgery on patients with stage IIIA lung cancer was also useful in terms of cost-effectiveness. In the future, it is necessary to analyze the cost-benefit analysis of the QALY and the new treatment cost due to deterioration of QOL at relapse and relapse by long-term simulation using Markov model.